Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.
Stuenkel CA¹, Davis SR¹, Gompel A¹, Lumsden MA¹, Murad MH¹, Pinkerton JV¹, Santen RJ¹.
J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011.
CONCLUSIONS:
Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
COMMENT-A very important and thorough study that basically rewrites much of medical advice given for a couple of decades, and that will have enormous impact on treatment menopasal women